Jiansong Ji

6PUBLICATIONS
1CO-AUTHORS
Predictive and prognostic markersCardiology (incl. cardiovascular diseases)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 05, 2021
LncRNA-SNHG6 promotes the progression of hepatocellular carcinoma by targeting miR-6509-5p and HIF1A.

Xiaoxi Fan, Zhongwei Zhao, Jingjing Song

|Nov 23, 2020
Management of patients with intermediate stage hepatocellular carcinoma.

David Prince, Ken Liu, Weiqi Xu

|Nov 19, 2020
Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.

Zhongwei Zhao, Dengke Zhang, Fazong Wu

|Aug 07, 2019
Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives.

Weiqi Xu, Ken Liu, Minjiang Chen

|Nov 30, 2018
LINC00707 contributes to hepatocellular carcinoma progression via sponging miR-206 to increase CDK14.

Jianfei Tu, Zhongwei Zhao, Min Xu

|Aug 19, 2018
Global microarray profiling identified hsa_circ_0064428 as a potential immune-associated prognosis biomarker for hepatocellular carcinoma.

Qiaoyou Weng, Minjiang Chen, Maoquan Li

Pageof 1

Frequent Collaborators

1 joint publications

David Prince